INVIVYD, INC. Operating Cash Flow
INVIVYD, INC. (IVVD) reported Operating Cash Flow of -$84.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- INVIVYD, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$43.01M.
- INVIVYD, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$41.71M.
- INVIVYD, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$15.46M.
- INVIVYD, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$8.25M.
- INVIVYD, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$58.13M.
- INVIVYD, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$170.49M.
- INVIVYD, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$173.16M.
- INVIVYD, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$219.99M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 4 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 7 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$43.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$84.72M 10-Q · filed 2026-08-13 | -$100.17M derived: sum of 3 quarters · filed 2026-08-13 | -$108.42M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$41.71M 10-Q · filed 2026-05-14 | -$57.17M derived: sum of 2 quarters · filed 2026-05-14 | -$65.42M derived: sum of 3 quarters · filed 2026-05-14 | -$78.72M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$15.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$23.70M derived: sum of 2 quarters · filed 2026-03-05 | -$37.01M derived: sum of 3 quarters · filed 2026-08-13 | -$58.13M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$8.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$21.55M derived: sum of 2 quarters · filed 2026-08-13 | -$42.68M 10-Q · filed 2025-11-06 | -$80.29M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$13.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$34.43M 10-Q · filed 2026-08-13 | -$72.04M derived: sum of 3 quarters · filed 2026-08-13 | -$113.11M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$21.13M 10-Q · filed 2026-05-14 | -$58.74M derived: sum of 2 quarters · filed 2026-05-14 | -$99.81M derived: sum of 3 quarters · filed 2026-05-14 | -$141.41M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$37.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$78.68M derived: sum of 2 quarters · filed 2026-03-05 | -$120.28M derived: sum of 3 quarters · filed 2026-03-05 | -$170.49M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$41.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$82.67M derived: sum of 2 quarters · filed 2025-11-06 | -$132.88M 10-Q · filed 2025-11-06 | -$192.12M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | -$41.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$91.81M 10-Q · filed 2025-08-14 | -$151.05M derived: sum of 3 quarters · filed 2025-08-14 | -$186.41M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | -$50.21M 10-Q · filed 2025-05-15 | -$109.45M derived: sum of 2 quarters · filed 2025-05-15 | -$144.81M derived: sum of 3 quarters · filed 2025-05-15 | -$182.20M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$59.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$94.59M derived: sum of 2 quarters · filed 2025-03-20 | -$131.98M derived: sum of 3 quarters · filed 2025-03-20 | -$173.16M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | -$35.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$72.74M derived: sum of 2 quarters · filed 2024-11-14 | -$113.92M 10-Q · filed 2024-11-14 | -$161.33M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$37.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$78.57M 10-Q · filed 2024-08-14 | -$125.98M derived: sum of 3 quarters · filed 2024-08-14 | -$182.12M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$41.18M 10-Q · filed 2024-05-09 | -$88.58M derived: sum of 2 quarters · filed 2024-05-09 | -$144.73M derived: sum of 3 quarters · filed 2024-05-09 | -$202.12M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$47.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$103.55M derived: sum of 2 quarters · filed 2024-03-28 | -$160.94M derived: sum of 3 quarters · filed 2024-03-28 | -$219.99M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$56.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$113.53M derived: sum of 2 quarters · filed 2023-11-09 | -$172.58M 10-Q · filed 2023-11-09 | -$245.79M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-06-30 | -$57.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$116.44M 10-Q · filed 2023-08-10 | -$189.65M derived: sum of 3 quarters · filed 2024-02-09 | -$243.87M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2022-03-31 | -$59.05M 10-Q · filed 2023-05-11 | -$132.26M derived: sum of 2 quarters · filed 2024-02-09 | -$186.47M derived: sum of 3 quarters · filed 2024-02-09 | -$220.04M derived: sum of 4 quarters · filed 2024-02-09 | ||
| 2021-12-31 | -$73.21M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | -$127.42M derived: sum of 2 quarters · filed 2024-02-09 | -$161.00M derived: sum of 3 quarters · filed 2024-02-09 | -$184.74M 8-K · filed 2024-02-09 | ||
| 2021-09-30 | -$54.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$87.78M derived: sum of 2 quarters · filed 2022-11-10 | -$111.52M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$33.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$57.31M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | -$23.74M 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | -$14.57M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | -$1.14M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |